Display Settings:

Format

Send to:

Choose Destination

    FASEB J. 2005 Jul;19(9):1123-4. Epub 2005 Apr 27.

    Maspin alters the carcinoma proteome.

    Chen EI, Florens L, Axelrod FT, Monosov E, Barbas CF 3rd, Yates JR 3rd, Felding-Habermann B, Smith JW.

    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA. emilyc@scripps.edu

    Maspin, a member of the serine protease inhibitor (serpin) family, is a tumor suppressor in breast and prostate cancer. To address molecular mechanisms underlying maspin's activity, we restored its expression in invasive carcinoma cells and analyzed the resulting changes by shotgun proteomics. Using a mass spectrometry-based multidimensional proteomic method, we observed changes to the expression of approximately 27% of the detectable proteome. In particular, we noted changes to the expression of proteins that regulate cytoskeletal architecture, cell death, and protein turnover. In each case, changes in protein expression were accompanied by measurable changes in tumor cell phenotype. Thus, maspin-expressing cells exhibit a more prominent actin cytoskeleton, a reduced invasive capacity, an increased rate of spontaneous apoptosis, and an altered proteasome function. These observations reveal for the first time the far reaching effects of maspin on multiple protein networks and a new hypothesis of maspin function based on the regulation of proteasome function.

    PMID: 15857880 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read